METTL3 and melanoma: To assess the therapeutic potential of METTL3 inhibition in ICB therapy, we administered a PD‐1 monoclonal antibody (anti‐PD‐1) and STM2457 to immunocompetent C57BL/6 mice bearing B16 melanoma cells (Figure 2A).